Cargando…
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Recent changes in lung cancer care, including new approvals in first line and the introduction of high-throughput molecular technologies in routine testing led us to question ourselves on how deeper molecular testing may be helpful for the optimal use of targeted drugs. In this article, we review re...
Autores principales: | Garinet, Simon, Laurent-Puig, Pierre, Blons, Hélène, Oudart, Jean-Baptiste |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024886/ https://www.ncbi.nlm.nih.gov/pubmed/29890761 http://dx.doi.org/10.3390/jcm7060144 |
Ejemplares similares
-
Updated Prognostic Factors in Localized NSCLC
por: Garinet, Simon, et al.
Publicado: (2022) -
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
por: Perrier, Alexandre, et al.
Publicado: (2020) -
Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
por: Bayle, Arnaud, et al.
Publicado: (2021) -
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
por: Torres, A., et al.
Publicado: (2014) -
Erratum to: Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
por: Torres, A., et al.
Publicado: (2014)